Earle A. Chiles Research Institute

Florida woman with metastatic pancreatic cancer participates in groundbreaking clinical trial of adoptive cellular therapy only available at Providence Cancer Institute.

Two new clinical trials available at Providence will evaluate whether a combination of medications are effective and safe therapies for people with metastatic melanoma and metastatic uveal melanoma.

Researchers of the Earle A. Chiles Research Institute, a division of Providence Cancer Institute of Oregon, will present their latest cancer immunotherapy data at Immunology2022 in May.

Investigator-initiated clinical trial at Providence Cancer Institute to evaluate the safety and efficacy of using a combination of immunotherapy and radiation therapy on tumors.

A new phase I clinical trial available at Providence Cancer Institute of Oregon will evaluate the efficacy of new immunotherapy designed to modulate the immune system in blood cancer patients.

Clinical studies focus on finding new ways to treat colorectal cancer, prevent recurrence and improve survival outcomes.

People with gallbladder cancer, bile duct cancer or pancreatic cancer may be eligible to participate in new clinical trials available at Providence Cancer Institute of Oregon.

Providence initiatives in genomic medicine, immunotherapy research and cancer screening support Cancer Moonshot's goal to decrease the death rate from cancer by 50 percent in 25 years.

Researchers at Providence Cancer Institute are studying how well two surgical procedures work in reducing the risk of ovarian cancer for women with BRCA1 mutations.

How Providence caregivers helped a young mother of four navigate COVID-19 and overcome a devastating cancer diagnosis.

A new study at Providence Cancer Institute tests the effectiveness of an experimental treatment and chemotherapy to inhibit tumor growth in people with lung cancer.

While tobacco is by far the leading cause of lung cancer, it's not the only contributor. Learn about other significant risk factors and what you can do to protect yourself and your loved ones.

Researchers at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute in Portland, Oregon, joined leading cancer immunotherapy professionals around the world for the largest

Providence Cancer Institute breast cancer experts are researching new treatments for women with triple-negative breast cancer and HER-2 positive breast cancer.

Experts in biomedical engineering, immunology and surgical oncology are working collaboratively to improve outcomes for people with head, neck and other cancers.

Providence Cancer Institute to open new clinical study of CAR T-cell therapy to people with clear cell renal cell carcinoma, the most common type of kidney cancer.

First-in-human immune therapy study at Providence Cancer Institute will assess the safety and effectiveness of talquetamab as a potential treatment for cancerous plasma cells known as multiple myeloma

Providence researchers awarded funding from National Cancer Institute to study “Bugs as Drugs.”

Providence Cancer Institute’s Rectal Cancer Program among the first 25 in the nation to earn accreditation from the National Accreditation Program for Rectal Cancer.